The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 20, 2017

Filed:

Apr. 24, 2015
Applicants:

Strike Bio, Inc, Dallas, TX (US);

Baylor College of Medicine, Houston, TX (US);

Inventors:

Donald Rao, Dallas, TX (US);

John Nemunaitis, Cedar Hill, TX (US);

Bert W. O'Malley, Houston, TX (US);

David Lonard, Pearland, TX (US);

Assignees:

STRIKE BIO, INC., Dallas, TX (US);

BAYLOR COLLEGE OF MEDICINE, Houston, TX (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/7088 (2006.01); A61K 45/06 (2006.01); C12Q 1/68 (2006.01); G01N 33/50 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61K 9/127 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1135 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); C12N 15/1136 (2013.01); C12N 15/1137 (2013.01); C12N 15/1138 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5011 (2013.01); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/31 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/914 (2013.01);
Abstract

The present invention includes compositions and methods for making and using a RNAi capable of reducing expression of two or more genes, comprising: a first RNAi molecule that reduces the expression of a first target gene; a second RNAi molecule that reduces the expression of the first or a second target gene; and optionally a third RNAi molecule that reduces the expression of the first, the second, or a third target gene, wherein the RNAi molecules reduce the expression level of, e.g., mutated KRAS, SRC-3, EGFR, PIK3, NCOA3, or ERalpha1, and can be, e.g., miRNAs, shRNAs, or bifunctional shRNAs.


Find Patent Forward Citations

Loading…